LOS ANGELES, September 27, 2022 – Leading international law firm Proskauer today announced that it advised Benitec Biopharma (Nasdaq: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company, on its recent capital raise.
Benitec develops novel genetic medicines based on a proprietary DNA-directed RNA interference ("ddRNAi") platform. They intend to use the net proceeds from this financing for the clinical development of BB-301, including the natural history lead-in study and the Phase 1b/2a BB-301 treatment study. The financing will also be used for the continued advancement of development activities for other existing and new product candidates as well as for general corporate purposes and for strategic growth opportunities.
The Proskauer team was led by partners Matthew O'Loughlin (M&A and Capital Markets) and Louis Rambo (Capital Markets). It also included partner Malcolm Hochenberg and associate Bowon Koh (Tax); and associates Perry Laub and Wilderness Castillo-Dobson (Capital Markets).
We are 800+ lawyers serving clients from 12 offices located in the leading financial and business centers in the Americas, Europe and Asia. The world's leading organizations, companies and corporations choose us to be their representatives in their most critical situations. But more, they consider Proskauer a strategic partner to drive their business forward. We work with asset managers, major sports leagues, Fortune 500 companies, entertainment industry legends and other industry-redefining companies.
Our Capital Markets Group includes lawyers across the U.S., Europe and Latin America. We represent bulge bracket, middle-market and boutique investment banks, as well as public and private companies of all sizes and industries around the world, in a wide variety of public, Rule 144A and Regulation S, and private debt and equity transactions. Our clients turn to us for our ability to lead the market in terms of innovation and financial structuring, the depth of our global team and our creative thought leadership.